[go: up one dir, main page]

SV2004001560A - Uso de inhibidores de vasopeptidasa en el tratamiento de enfermedades metabolicas, nefropatia y enfermedades asociadas con age - Google Patents

Uso de inhibidores de vasopeptidasa en el tratamiento de enfermedades metabolicas, nefropatia y enfermedades asociadas con age

Info

Publication number
SV2004001560A
SV2004001560A SV2003001560A SV2003001560A SV2004001560A SV 2004001560 A SV2004001560 A SV 2004001560A SV 2003001560 A SV2003001560 A SV 2003001560A SV 2003001560 A SV2003001560 A SV 2003001560A SV 2004001560 A SV2004001560 A SV 2004001560A
Authority
SV
El Salvador
Prior art keywords
diabetic
treatment
diseases
nephropatia
metabolic diseases
Prior art date
Application number
SV2003001560A
Other languages
English (en)
Inventor
Stefan Schafer
Wolfgang Linz
Markus Bleich
Jochen Huber
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of SV2004001560A publication Critical patent/SV2004001560A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

USO DE INHIBIDORES DE VASOPEPTIDASA DE LA FORMULA (I) PARA EL TRATAMIENTO Y/O PROFILAXIS DE NEFROPATIA EN PACIENTES DIABETICOS O NO DIABETICOS, INCLUIDA LA NEFROPTIA DIABETICA O NO DIABETICA , GLOMERULONEFRITIS , ESCLEROSIS GLOMERULAR , SINDROME NEFROTICO, NEFROESCLEROSIS HIPERTENSIVA, MICROALBUMINURIA O ENFERMEDAD RENAL DE FASE TERMINAL, O RESISTENCIA A LA INSULINA O DE ENFERMEDADES METABOLICAS ASOCIADAS CON PRODUCTOS FINALES, DE GLICACION AVANZADA TALES COMO COMPLICACIONES DIABETICAS, NEUROPATIA DIABETICA, NEFROPATIA DIABETICA , RETINOPATIA DIABETICA, CATARATAS, INFARTO DE MIOCARDIO Y/O CARDIOMIOPATIA DIABETICA , O ATEROSCLEROSIS O DISFUNCION ENDOTELIAL.
SV2003001560A 2002-06-28 2003-06-23 Uso de inhibidores de vasopeptidasa en el tratamiento de enfermedades metabolicas, nefropatia y enfermedades asociadas con age SV2004001560A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2002129180 DE10229180A1 (de) 2002-06-28 2002-06-28 Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen

Publications (1)

Publication Number Publication Date
SV2004001560A true SV2004001560A (es) 2004-02-26

Family

ID=29795983

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2003001560A SV2004001560A (es) 2002-06-28 2003-06-23 Uso de inhibidores de vasopeptidasa en el tratamiento de enfermedades metabolicas, nefropatia y enfermedades asociadas con age

Country Status (38)

Country Link
US (2) US6930103B2 (es)
EP (1) EP1519732B1 (es)
JP (1) JP4564354B2 (es)
KR (1) KR101072235B1 (es)
CN (1) CN100366254C (es)
AR (1) AR040343A1 (es)
AT (1) ATE548040T1 (es)
AU (1) AU2003280440B2 (es)
BR (1) BR0312250A (es)
CA (1) CA2490277C (es)
CR (1) CR7667A (es)
CY (1) CY1112905T1 (es)
DE (1) DE10229180A1 (es)
DK (1) DK1519732T3 (es)
EC (1) ECSP045513A (es)
ES (1) ES2383889T3 (es)
HN (1) HN2003000193A (es)
HR (1) HRP20041212B1 (es)
IL (2) IL165935A0 (es)
MA (1) MA27281A1 (es)
MX (1) MXPA04012230A (es)
NO (1) NO334811B1 (es)
NZ (1) NZ537480A (es)
OA (1) OA12871A (es)
PA (1) PA8576501A1 (es)
PE (1) PE20040582A1 (es)
PL (1) PL218070B1 (es)
PT (1) PT1519732E (es)
RS (1) RS52478B (es)
RU (1) RU2336080C2 (es)
SI (1) SI1519732T1 (es)
SV (1) SV2004001560A (es)
TN (1) TNSN04262A1 (es)
TW (1) TWI326215B (es)
UA (1) UA82845C2 (es)
UY (1) UY27869A1 (es)
WO (1) WO2004002492A1 (es)
ZA (1) ZA200409382B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2482546C2 (ru) * 2011-04-28 2013-05-20 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к с-концевому фрагменту рецептора ангиотензина ii

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430145A (en) * 1990-10-18 1995-07-04 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
CA2053340C (en) * 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
ATE138645T1 (de) * 1991-03-01 1996-06-15 Zeria Pharm Co Ltd Indan-derivate als thromboxan-antagonisten
RU2098411C1 (ru) * 1991-08-02 1997-12-10 Иституто Лусо Фармако д Италия С.п.А. Производные пиримидина, способ их получения, фармацевтическая композиция на их основе
ES2106112T3 (es) * 1991-09-27 1997-11-01 Merrell Pharma Inc Derivados de indano-2-mercaptoacetilamida con una actividad inhibidora de encefalinasa y de ace.
WO1993016103A1 (en) * 1992-02-14 1993-08-19 Merrell Dow Pharmaceuticals Inc. Aminoacetylmercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
US5484783A (en) * 1994-03-24 1996-01-16 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives
ATE189392T1 (de) * 1994-03-24 2000-02-15 Merrell Pharma Inc Hypocholesterolemische, antiatherosklerotische und hypotriglyceridemische verwendung von aminoacetylmercapto derivaten
CA2224451A1 (en) * 1995-06-30 1997-01-23 Merck & Co., Inc. Method of treating renal disease using an ace inhibitor and an aii antagonist
BR9612316A (pt) 1995-12-27 1999-07-13 Yoshitomi Pharmaceutical Agente para profilaxia e tratamento de complicações diabéticas
RU2276997C2 (ru) * 1999-08-30 2006-05-27 Санофи-Авентис Дойчланд Гмбх Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений
US6149915A (en) 1999-09-29 2000-11-21 Shiva Biomedical, Llc Treatment of diabetic nephropathy and microalbuminuria
EP1381605B1 (en) * 2001-04-12 2005-01-12 Aventis Pharma Deutschland GmbH Mercaptoacetylamide derivatives, a process for their preparation and their use
US20030040509A1 (en) * 2001-08-06 2003-02-27 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ACE

Also Published As

Publication number Publication date
PA8576501A1 (es) 2004-02-07
DK1519732T3 (da) 2012-06-18
NZ537480A (en) 2005-11-25
TWI326215B (en) 2010-06-21
ECSP045513A (es) 2005-03-10
AR040343A1 (es) 2005-03-30
EP1519732B1 (en) 2012-03-07
RU2005102087A (ru) 2005-07-10
DE10229180A1 (de) 2004-01-29
UY27869A1 (es) 2003-12-31
NO334811B1 (no) 2014-06-02
PL218070B1 (pl) 2014-10-31
CA2490277C (en) 2011-11-01
UA82845C2 (en) 2008-05-26
TW200406214A (en) 2004-05-01
RS52478B (sr) 2013-02-28
BR0312250A (pt) 2005-04-26
KR20050013642A (ko) 2005-02-04
US6930103B2 (en) 2005-08-16
OA12871A (en) 2006-09-15
ATE548040T1 (de) 2012-03-15
CN100366254C (zh) 2008-02-06
PE20040582A1 (es) 2004-10-18
US20050171090A1 (en) 2005-08-04
JP4564354B2 (ja) 2010-10-20
JP2005533815A (ja) 2005-11-10
HRP20041212A2 (en) 2005-06-30
EP1519732A1 (en) 2005-04-06
KR101072235B1 (ko) 2011-10-12
WO2004002492A1 (en) 2004-01-08
HN2003000193A (es) 2004-10-27
IL165935A (en) 2010-12-30
TNSN04262A1 (en) 2007-03-12
ES2383889T3 (es) 2012-06-27
RU2336080C2 (ru) 2008-10-20
AU2003280440A1 (en) 2004-01-19
CN1665512A (zh) 2005-09-07
MXPA04012230A (es) 2005-02-25
CA2490277A1 (en) 2004-01-08
CY1112905T1 (el) 2016-04-13
MA27281A1 (fr) 2005-04-01
CR7667A (es) 2005-06-16
PL372992A1 (en) 2005-08-08
HRP20041212B1 (hr) 2013-06-30
RS100704A (sr) 2007-02-05
NO20050425L (no) 2005-01-25
ZA200409382B (en) 2006-01-25
SI1519732T1 (sl) 2012-05-31
AU2003280440B2 (en) 2009-07-16
HK1079435A1 (zh) 2006-04-07
US20040058911A1 (en) 2004-03-25
IL165935A0 (en) 2006-01-15
US7514423B2 (en) 2009-04-07
PT1519732E (pt) 2012-05-22

Similar Documents

Publication Publication Date Title
MX2013008484A (es) Prevencion de hidroglucemia en pacientes con diabetes mellitus tipo 2.
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
WO2003033524A3 (en) Peptidyl ketones as inhibitors of dpiv
MX2007003161A (es) Derivado de triazol o una sal del mismo.
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
IL186566A0 (en) Substituted 2-amin0alkylth10-benzimidaz0les and use thereof for reducing blood sugar levels
WO2006000567A3 (en) Use of glp-1 receptor agonists and / or dpp-iv inhibitors in combination with proton pump inhibitors and ppar agonists for the preparation of a medicament for the treatment of diabetes type i i and impaired pancreatic beta-cell function
WO2008108958A3 (en) Benzimidazole derivatives and methods of use thereof
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
UA92355C2 (en) urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS
UA105216C2 (en) Pharmaceutical composition
NO20084321L (no) Triazolderivat eller salt derav
CY1112398T1 (el) Πυρρολιδινονες υποκατασταθεισες απο κυκλοεξυλιο ως αναστολεις της 11-β-υδροξυστεροειδικης αφυδρογονασης 1
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
ATE430743T1 (de) Benzimidazolsubstituierte thiophenderivate, die auf ikk3 wirken
AR054525A1 (es) Composiciones y metodos para eltratamiento de sintomas relacionados con el ciclo
WO2007009389A3 (fr) Derives de propanamide substitues, preparation et utilisation de ces derives
PA8567301A1 (es) Nuevos derivados de tiazol como antagonistas del receptor npy
MX2010009577A (es) Derivados de piridopirazinona que estimulan la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.
SV2004001560A (es) Uso de inhibidores de vasopeptidasa en el tratamiento de enfermedades metabolicas, nefropatia y enfermedades asociadas con age
WO2020219645A3 (en) Methods for reducing the weight loss or increasing the weight of a feline in need thereof
GEP20125685B (en) Acupuncture needle of prolonged action for acusal tracts formation
PH12013500711A1 (en) Acylbenzene derivative
WO2007116297A3 (en) Use of aminapthone for the preparation of a medicament for treating arteriophaties
PA8576701A1 (es) Derivados de quinazolina

Legal Events

Date Code Title Description
FC Refusal